Detecting small cell lung cancer using autoantibodies as biomarkers
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-10896444
This study is looking for ways to find small cell lung cancer earlier by checking for certain antibodies in the blood of people, especially heavy smokers, and using imaging tests to spot tumors, which could help catch the cancer sooner and improve treatment outcomes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10896444 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the early detection of small cell lung cancer (SCLC) by identifying specific autoantibodies present in the blood of patients. The approach involves a two-tiered strategy that combines a blood test to detect these autoantibodies with non-invasive imaging techniques to confirm the presence of tumors. By targeting high-risk individuals, particularly heavy smokers, the research aims to facilitate timely diagnosis and treatment, potentially improving survival rates. The study leverages previously validated cancer-specific neoantigens to enhance the accuracy of detection.
Who could benefit from this research
Good fit: Ideal candidates for this research are heavy smokers or individuals at high risk for developing small cell lung cancer.
Not a fit: Patients who do not smoke or have no other risk factors for small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the early detection rates of small cell lung cancer, leading to better treatment outcomes and improved survival rates.
How similar studies have performed: Previous research has shown promise in using autoantibodies as biomarkers for cancer detection, indicating that this approach may be effective.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAMPE, PAUL D. — FRED HUTCHINSON CANCER CENTER
- Study coordinator: LAMPE, PAUL D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.